John Paulson (Trades, Portfolio) is the president and portfolio manager of Paulson & Co. Inc. Paulson was ranked by Absolute Return Magazine as the third-largest hedge fund in the world managing approximately $29 billion in merger, event and distressed strategies. During the fourth quarter, the guru bought the following stocks.
Paulson raised his stake in Valeant Pharmaceuticals International Inc. (VRX) by 49.22% and the deal had an impact of 2.74% on the portfolio.
It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products OTC and medical devices. During the third quarter despite negative foreign exchange impact, total revenues increased 36% over the prior year and same store sales had organic growth of 13%.
GuruFocus gives the stock a profitability and growth rating of 9 out of 10 with ROE of -5.07% and ROA of -0.79%.
Ruane Cunniff (Trades, Portfolio) is the largest shareholder of the company among the gurus with 10.31% of outstanding shares, followed by Bill Ackman (Trades, Portfolio) with 8.95%, Jeff Ubben (Trades, Portfolio) with 4.37%, Andreas Halvorsen (Trades, Portfolio) with 02.27%, Glenn Greenberg (Trades, Portfolio) with 1.82% and Steve Mandel (Trades, Portfolio) with 1.7%.
Paulson bought 5,000,000 shares of Lam Research Corp. (LRCX) with an impact of 2.44% on the portfolio.
The company is a supplier of wafer fabrication equipment and services to the semiconductor industry. It designs, manufactures, markets and services semiconductor processing systems that are used in the fabrication of integrated circuits.
GuruFocus gives the stock a profitability and growth rating of 7 out of 10 with ROE of 16.26% and ROA of 9.22% that outperform 82% of the companies in the Global Semiconductor Equipment & Materials industry. Financial strength has a rating of 8 out of 10, with a cash-to-debt of 1.88 that is above the industry median of 1.66.
Other notable shareholders among the gurus are Joel Greenblatt (Trades, Portfolio) with 0.65% of outstanding shares, followed by Jim Simons (Trades, Portfolio) with 0.48%, Steven Cohen (Trades, Portfolio) with 0.44%, RS Investment Management (Trades, Portfolio) with 0.14%, Pioneer Investments (Trades, Portfolio) with 0.11% and Louis Moore Bacon (Trades, Portfolio) with 0.05%.
Paulson raised his stake in Teva Pharmaceutical Industries Ltd. (TEVA) by 13.39% and the deal had an impact of 10.97% on the portfolio.
The company manufactures generic pharmaceutical products. Fourth quarter revenue grew 4% and operating income grew 9% year over year.
GuruFocus gives the stock a profitability and growth rating of 7 out of 10 with ROE of 6.47% and ROA of 3.22% that are underperforming 52% of the companies in the industry. Financial strength has a rating of 6 out of 10, with a cash-to-debt of 0.70 that is below the industry median of 3.32.
Andreas Halvorsen (Trades, Portfolio) is the largest shareholder of the company among the gurus with 2.76% of outstanding shares, followed by Barrow, Hanley, Mewhinney & Strauss with 1.06%, Larry Robbins (Trades, Portfolio) with 0.66%, Vanguard Health Care Fund (Trades, Portfolio) with 0.64%, First Eagle Investment (Trades, Portfolio) with 0.48% and John Griffin (Trades, Portfolio) with 0.44%.
Paulson increased his stake in Mallinckrodt PLCÂ (MNK) by 30.78% and the deal had an impact of 0.93% on the portfolio.
The company operates in a specialty biopharmaceutical and nuclear imaging business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and nuclear imaging agents. First quarter net sales grew 20.3% on an operational basis year over year.
GuruFocus gives the stock a profitability and growth rating of 6 out of 10. Financial strength has a rating of 7 out of 10, with a cash-to-debt of 0.08 that is below the industry median of 3.32.
Other notable shareholders among the gurus are Ken Heebner (Trades, Portfolio) with 7.71% of outstanding shares, followed by Louis Moore Bacon (Trades, Portfolio) with 0.02%, Paul Tudor Jones (Trades, Portfolio) with 0.01%, George Soros (Trades, Portfolio) with 0.01% and Mario Gabelli (Trades, Portfolio) with 0.01%.
Paulson raised his stake in Grifols SAÂ (GRFS) by 39.86% and the deal had an impact of 0.7% on the portfolio.
It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Grifols’ net profit rose by 18.5% year over year in the third quarter.
GuruFocus gives the stock a profitability and growth rating of 8 out of 10 with ROE of 17.33% and ROA of 5.82% that are outperforming 84% of the companies in the Global Biotechnology industry. Financial strength has a rating of 6 out of 10 with no debt.
Paulson increased his stake in Endo International PLCÂ (ENDP) by 93.11% and the deal had an impact of 0.6% on the portfolio.
It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. During the third quarter, revenues grew 14% year over year.
GuruFocus gives the stock a profitability and growth rating of 4 out of 10 with ROE of -29.86% and ROA of -9.12% that are underperforming 87% of the companies in the industry. Financial strength has a rating of 5 out of 10, with a cash-to-debt of 0.03 that is far below the industry median of 3.32.
The largest shareholder among the gurus is Andreas Halvorsen (Trades, Portfolio) with 2.03% of outstanding shares, followed by George Soros (Trades, Portfolio) with 0.97%, John Griffin (Trades, Portfolio) with 0.92%, Wallace Weitz (Trades, Portfolio) with 0.31%, RS Investment Management (Trades, Portfolio) with 0.24% and Steven Cohen (Trades, Portfolio) with 0.18%.
Paulson bought 632,700 shares in Pfizer Inc. (PFE) with an impact of 0.13% on the portfolio.
The company applies science and its resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products.
GuruFocus gives the stock a profitability and growth rating of 6 out of 10 with ROE of 10.32% and ROA of 4.20% that are outperforming 52% of the companies in the industry. Financial strength has a rating of 7 out of 10, with a cash-to-debt of 0.60 that is below the industry median of 3.32.
Barrow, Hanley, Mewhinney & Strauss is the largest shareholder of the company among the gurus with 0.87% of outstanding shares, followed by Ken Fisher (Trades, Portfolio) with 0.52%, T Rowe Price Equity Income Fund (Trades, Portfolio) with 0.23%, Lee Ainslie (Trades, Portfolio) with 0.18%, Diamond Hill Capital (Trades, Portfolio) with 0.17% and Jana Partners (Trades, Portfolio) with 0.15%.
